{"id":384999,"date":"2020-11-19T08:33:14","date_gmt":"2020-11-19T13:33:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384999"},"modified":"2020-11-19T08:33:14","modified_gmt":"2020-11-19T13:33:14","slug":"chemocentryx-to-present-at-two-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/","title":{"rendered":"ChemoCentryx to Present at Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MOUNTAIN VIEW, Calif., Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:<\/p>\n<p>\n        <strong>Piper Sandler 32nd Annual Virtual Healthcare<\/strong><br \/>\n        <strong>Conference<\/strong><br \/>\n        <br \/>On-demand presentation available beginning Monday, November 23 at\u00a010:00 a.m.\u00a0Eastern Time<\/p>\n<p>\n        <strong>Evercore ISI 3rd Annual <\/strong><br \/>\n        <strong>HealthCONx<\/strong><br \/>\n        <strong> Conference<\/strong><br \/>\n        <br \/>Thursday, December 3, 2020 at 1:25 p.m. Eastern Time<\/p>\n<p>A live audio webcast of the Evercore presentation and the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company&#8217;s website at www.ChemoCentryx.com. Both webcasts will be available on the Company&#8217;s website for two weeks following the respective presentation dates.<\/p>\n<p>\n        <strong>About\u00a0ChemoCentryx<\/strong>\n      <\/p>\n<p>ChemoCentryx\u00a0is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.\u00a0ChemoCentryx\u00a0targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx\u2019s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the\u00a0U.S. Food and Drug Administration, along with a Marketing Authorization Application by the European Medicines Agency. Avacopan is also in late stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).<\/p>\n<p>ChemoCentryx\u00a0also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">Susan M. Kanaya<br \/>Executive Vice President,<br \/>Chief Financial and Administrative Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5S9DD1_TrWYGsXK5IdKVKfMF_9Qfe9Z-hS-hUcI7WKqfxdSAUGJsIfm8P4DvIjNLQRC-ecHD6tLMMgZL5qO_uyaX82Jwg4mz3i0vGggcE3s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@chemocentryx.com<\/a><\/p>\n<p>Media:<br \/>Stephanie Tomei<br \/>408.234.1279<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ns3lDPFRkFTbELpmT2KF6GAbeEbqw3onqS1xTIfU68MSaed0NzPP7u5AoRRI4n8UxhEEJsssyBHpxkr_vyRA8B6IUPQZYGpES7p0Z1o8bJk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@chemocentryx.com<\/a><\/p>\n<p>Investors:<br \/>Lee Roth, Burns McClellan<br \/>212.213.0006<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=25jJyIV-0L5IuxEmKsucAhbhsmX23gQ4TBSwlla9TCwb2naZSm9huG1edOvkYM-7RID5jyL50lyBlU_VLd5YJA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lroth@burnsmc.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8862c47b-6bb5-4a0c-adc2-4ab9549b6467\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference On-demand presentation available beginning Monday, November 23 at\u00a010:00 a.m.\u00a0Eastern Time Evercore ISI 3rd Annual HealthCONx Conference Thursday, December 3, 2020 at 1:25 p.m. Eastern Time A live audio webcast of the Evercore presentation and the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company&#8217;s website at www.ChemoCentryx.com. Both webcasts will be available on the Company&#8217;s website for two weeks following the respective presentation dates. About\u00a0ChemoCentryx ChemoCentryx\u00a0is a biopharmaceutical company developing new medications for inflammatory and autoimmune &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ChemoCentryx to Present at Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384999","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference On-demand presentation available beginning Monday, November 23 at\u00a010:00 a.m.\u00a0Eastern Time Evercore ISI 3rd Annual HealthCONx Conference Thursday, December 3, 2020 at 1:25 p.m. Eastern Time A live audio webcast of the Evercore presentation and the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company&#8217;s website at www.ChemoCentryx.com. Both webcasts will be available on the Company&#8217;s website for two weeks following the respective presentation dates. About\u00a0ChemoCentryx ChemoCentryx\u00a0is a biopharmaceutical company developing new medications for inflammatory and autoimmune &hellip; Continue reading &quot;ChemoCentryx to Present at Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T13:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ChemoCentryx to Present at Two Upcoming Investor Conferences\",\"datePublished\":\"2020-11-19T13:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/\",\"name\":\"ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\",\"datePublished\":\"2020-11-19T13:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ChemoCentryx to Present at Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk","og_description":"MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference On-demand presentation available beginning Monday, November 23 at\u00a010:00 a.m.\u00a0Eastern Time Evercore ISI 3rd Annual HealthCONx Conference Thursday, December 3, 2020 at 1:25 p.m. Eastern Time A live audio webcast of the Evercore presentation and the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company&#8217;s website at www.ChemoCentryx.com. Both webcasts will be available on the Company&#8217;s website for two weeks following the respective presentation dates. About\u00a0ChemoCentryx ChemoCentryx\u00a0is a biopharmaceutical company developing new medications for inflammatory and autoimmune &hellip; Continue reading \"ChemoCentryx to Present at Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T13:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ChemoCentryx to Present at Two Upcoming Investor Conferences","datePublished":"2020-11-19T13:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/","name":"ChemoCentryx to Present at Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=","datePublished":"2020-11-19T13:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODc2NSMzODM0NDk5IzIwMDY0MDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-present-at-two-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ChemoCentryx to Present at Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384999"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}